Skip to main content

Table 1 Dogs included in the study

From: Localized alopecia and suppression of hypothalamic-pituitary-adrenal (HPA) axis in dogs following treatment with difluprednate 0.05% ophthalmic emulsion (Durezol®)

Dog

Signalment

Weight (kg)

ADAMTS-10 Genotype (Phenotype)

AAV

Topical Steroid Treatment

Duration of Treatment

Description of Hair Coat Abnormalities

1a

3 years; M Beagle

12.6

Wildtype (normal)

OS

Difluprednate OU BID

764 days

Mild periocular alopecia OU

2

2 years; M Beagle

17.6

Homozygous mutant (OAG-affected)

OU

Difluprednate OU BID

102 days

None

3a

5 years; M Beagle

13.6

Homozygous mutant (OAG-affected)

OS

Difluprednate OU TID

1164 days

Generalized hypotrichosis and mild periocular alopecia OU

4

5 years; M Beagle

14.3

Homozygous mutant (OAG-affected)

OU

Difluprednate OU BID

102 days

None

5

2 years; F Beagle

10.3

Wildtype (normal)

OD

Difluprednate OD BID

667 days

Periocular alopecia OD

6

4 years; F Beagle

9.6

Homozygous mutant (OAG-affected)

OD

Difluprednate OD BID

764 days

Periocular alopecia OD and pinna alopecia AU

7

4 years; F Beagle

9.75

Homozygous mutant (OAG-affected)

OS

Difluprednate OS BID

764 days

Periocular alopecia OS, pinna alopecia AS, left palmar metacarpal alopecia

8

1.5 years; F Beagle

13.85

Homozygous mutant (OAG-affected)

OD

Difluprednate OU TID

102 days

None

9

1.5 years; M Beagle

11.8

Homozygous mutant (OAG-affected)

OS

Difluprednate OU TID

102 days

None

10

4 years; MN Beagle

12.6

Homozygous mutant (OAG-affected)

OU

None

N/A

None

11

4 years; F Beagle

10.8

Homozygous mutant (OAG-affected)

OU

None

N/A

None

12

3 years; F Beagle

12.25

Carrier (normal)

None

N/A

None

13

3 years; M Beagle

12.6

Wildtype (normal)

None

N/A

None

14

7 years; FS Chihuahua

5.5

Wildtype (normal)

Difluprednate OU BID

413 days

Generalized hypotrichosis

  1. Abbreviations: AD right ear; AS, left ear; AU, both ears; OAG, open-angle glaucoma; BID, twice daily; TID, three times daily; OD, right eye; OS, left eye; OU, both eyes; M, male; F, female; FS, female spayed; MN, male neutered
  2. a = Dogs initially treated with NPD and then subsequently transitioned to difluprednate
  3. AAV: All dogs intracameral, except for dog 8 OD, dog 10 OU, dog 11 OU – intravitreal